Trial Profile
A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Sep 2015
Price :
$35
*
At a glance
- Drugs Edifoligide (Primary)
- Indications Coronary artery restenosis; Vascular graft occlusion
- Focus Registrational; Therapeutic Use
- Acronyms PREVENT-IV
- Sponsors Corgentech
- 05 Nov 2010 New trial record.